These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30069687)

  • 1. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine.
    Shima H; Kutomi G; Satomi F; Imamura M; Kimura Y; Mizuguchi T; Watanabe K; Takahashi A; Murai A; Tsukahara T; Kanaseki T; Hirohashi Y; Iwayama Y; Tsuruma T; Kameshima H; Sato N; Torigoe T; Takemasa I
    Cancer Immunol Immunother; 2018 Oct; 67(10):1603-1609. PubMed ID: 30069687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
    Kubo T; Tsurita G; Hirohashi Y; Yasui H; Ota Y; Watanabe K; Murai A; Matsuo K; Asanuma H; Shima H; Wada S; Nakatsugawa M; Kanaseki T; Tsukahara T; Mizuguchi T; Hirata K; Takemasa I; Imai K; Sato N; Torigoe T
    Cancer Sci; 2019 Aug; 110(8):2386-2395. PubMed ID: 31206934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
    Shima H; Tsurita G; Wada S; Hirohashi Y; Yasui H; Hayashi H; Miyakoshi T; Watanabe K; Murai A; Asanuma H; Tokita S; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nakae Y; Sugita O; Ito YM; Ota Y; Kimura Y; Kutomi G; Hirata K; Mizuguchi T; Imai K; Takemasa I; Sato N; Torigoe T
    Cancer Sci; 2019 Aug; 110(8):2378-2385. PubMed ID: 31218770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
    Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K
    Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
    Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
    Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
    Tsuruma T; Iwayama Y; Ohmura T; Katsuramaki T; Hata F; Furuhata T; Yamaguchi K; Kimura Y; Torigoe T; Toyota N; Yagihashi A; Hirohashi Y; Asanuma H; Shimozawa K; Okazaki M; Mizushima Y; Nomura N; Sato N; Hirata K
    J Transl Med; 2008 May; 6():24. PubMed ID: 18471305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Probability of vaccine therapy for pancreas cancer].
    Takahashi M; Togou S; Yamaoka H; Ichikawa H; Shimada H; Cheever MA
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1676-8. PubMed ID: 8886043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Present and future status of therapeutic cancer peptide vaccine therapy for patients with pancreatic cancer].
    Katsuda M; Yamaue H
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():433-7. PubMed ID: 25857063
    [No Abstract]   [Full Text] [Related]  

  • 16. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
    Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
    Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.